Here are the 10-K annual reports from Alto Neuroscience Inc. (ANRO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience, Inc. describes a clinical-stage precision psychiatry business built around its proprietary biomarker-driven Platform and a pipeline of seven clinical assets targeting major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia-related cognitive impairment, and Parkinson’s disease.
Lead program ALTO-207, a fixed-dose combination of pramipexole and ondansetron, is being advanced for treatment-resistant depression with a Phase 2b trial planned for the first half of 2026 and a potential Phase 3 by early 2027. ALTO-300 (agomelatine) is in a Phase 2b adjunctive MDD study enriched by an EEG biomarker, with topline data expected mid-2026.
ALTO-100 is in a Phase 2b bipolar depression trial as adjunctive therapy, partially funded by an up to approximately $11.7 million convertible loan from Wellcome. ALTO-101, a transdermal PDE4 inhibitor for cognitive impairment associated with schizophrenia, has FDA Fast Track designation and a Phase 2 proof-of-concept study expected to read out around the end of the first quarter of 2026. Additional product candidates ALTO-203, ALTO-202, and ALTO-208 are supported by multiple in-licensing and asset purchase agreements, and the company reports a broad global patent estate with expected expiries extending into the 2040s.